July 29, 2019
Authored and Edited by Nicholas J. Doyle; Shana K. Cyr, Ph.D.
On July 22, 2019, FDA issued final guidance on postmarketing safety reporting (“PMSR”) for combination products. The guidance focuses on ways to comply with the PMSR rule for combination products that have received FDA marketing authorization.
After providing a background on combination products and how they are regulated, the guidance identifies general considerations for PMSR compliance. The guidance explains that the rule applies to two types of applicants: Combination Product Applicants and Constituent Part Applicants. Combination Product Applicants hold the only application(s) for a combination product. Examples of Combination Product Applicants are companies that hold an approved PMA for a drug-eluting stent, an approved NDA for a pre-metered dry powder inhaler co-packaged with a filled drug product cartridge, an approved BLA for a vaccine supplied in a pre-filled syringe, or both an approved PMA for a laser system for photoactivating a drug and an approved NDA for that drug.
Constituent Part Applicants hold an application for a constituent part of a combination product, where the applications for other parts are held by different applicants. Examples of Constituent Part Applicants include a company that holds an approved PMA for a laser system for activating a drug, where the approved NDA for the drug is held by a different company. Application type-based reporting requirements apply to both types of applicant, while constituent part-based reporting requirements apply only to Combination Product Applicants and information sharing requirements apply only to Constituent Part Applicants.
The guidance also discusses specific PMSR requirements in greater detail and identifies process considerations for Combination Product Applicants. It concludes with hypothetical examples to illustrate PMSR considerations for Combination Product Applicants and a chart of PMSR requirements by application and product type.
Readers are encouraged to read the final guidance, also available on FDA’s website.
Copyright © 2019 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
INCONTESTABLE® Blog
April 19, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.